<qa>  What is the name of the sub-group of patients that is at high risk for developing progressiveNAFLD encompasses an entire pathological spectrum of disease, from relatively benign accumulation of lipid steatosis to progressive non alcoholic steatohepatitis NASH associated with inflammation, fibrosis, and necrosis. It has been estimated that 20-30 of patients with NAFLD will exhibit biochemical and histological changes characteristic of NASH, and 15-20 of those patients will progress to have cirrhosis. NASH remains an important phenotypic state, because this sub-group of patients is deemed at high-risk for developing progressive disease resulting in cirrhosis, liver failure requiring transplantation, or death. 